Non-viral episomal suicide construct

US9879278B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9879278-B2
Application numberUS-201314382816-A
CountryUS
Kind codeB2
Filing dateFeb 27, 2013
Priority dateMar 5, 2012
Publication dateJan 30, 2018
Grant dateJan 30, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention includes compositions and methods for the selective expression of a target gene in a subset of cells. In certain embodiments, the present invention includes a construct comprising a first nucleic acid sequence comprising an episomal maintenance element and a second nucleic acid sequence comprising a target gene wherein the expression of the episomal maintenance element is regulated by a constitutive promoter and the expression of the target gene is regulated by a non-constitutive promoter. The construct is able to maintain episomal state, no matter whether the target gene is expressed in the cell.

First claim

Opening claim text (preview).

What is claimed is: 1. A vector comprising a first nucleic acid comprising a scaffold/matrix attached regions (S/MAR) episomal maintenance element sequence, and a second nucleic acid comprising a suicide gene, wherein the first nucleic acid comprises in 5′-3′ order, a constitutive promoter, a gene operably linked to the constitutive promoter, an (S/MAR) sequence and a polyadenylation signal, wherein transcription of the gene operably linked to the constitutive promoter, together with the S/MAR sequence and the polyadenylation signal, is controlled by the constitutive promoter, wherein the second nucleic acid comprises an undifferentiated stem cell specific promoter operably linked to the suicide gene, and wherein expression of the suicide gene is controlled by the undifferentiated stem cell specific promoter, further wherein when the suicide gene is expressed in an undifferentiated stem cell, the undifferentiated stem cell is susceptible to cell death, and wherein the undifferentiated stem cell specific promoter is selected from the group consisting of OCT4, hTERT, and NANOG, and the suicide gene encodes thymidine kinase (TK). 2. The vector of claim 1 , wherein the S/MAR episomal maintenance element sequence is capable of long term episomal maintenance of the vector in an entire cell population, and wherein the non-constitutive promoter is capable of expression of the suicide gene in a subset of cells of the entire cell population. 3. The vector of claim 1 , wherein the gene operatively linked to the constitutive promoter is Kan/Neo. 4. The vector of claim 1 , wherein the undifferentiated stem cell specific promoter is the promoter of OCT4 gene.

Assignees

Inventors

Classifications

  • Systems of functionally co-operating vectors · CPC title

  • C12N15/85Primary

    for animal cells · CPC title

  • cell or tissue specific · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9879278B2 cover?
The invention includes compositions and methods for the selective expression of a target gene in a subset of cells. In certain embodiments, the present invention includes a construct comprising a first nucleic acid sequence comprising an episomal maintenance element and a second nucleic acid sequence comprising a target gene wherein the expression of the episomal maintenance element is regulate…
Who is the assignee on this patent?
Univ Wake Forest Health Sciences
What technology area does this patent fall under?
Primary CPC classification C12N15/85. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).